Bifogade filer
CA260211-insider-trading
Kalender
| Est. tid* | ||
| 2026-11-04 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-05 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-06 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-03-27 | N/A | X-dag halvårsutdelning NOVO B 7.95 |
| 2026-03-26 | N/A | Årsstämma |
| 2026-02-04 | - | Bokslutskommuniké 2025 |
| 2025-11-14 | - | Extra Bolagsstämma 2025 |
| 2025-11-05 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | - | X-dag halvårsutdelning NOVO B 3.75 |
| 2025-08-06 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-28 | - | X-dag halvårsutdelning NOVO B 7.9 |
| 2025-03-27 | - | Årsstämma |
| 2025-02-05 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2024-08-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-02 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-22 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2024-03-21 | - | Årsstämma |
| 2024-01-31 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-13 | - | Split NOVO B 1:2 |
| 2023-08-18 | - | X-dag halvårsutdelning NOVO B 6 |
| 2023-08-10 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-24 | - | X-dag halvårsutdelning NOVO B 8.15 |
| 2023-03-23 | - | Årsstämma |
| 2023-02-01 | - | Bokslutskommuniké 2022 |
| 2022-11-02 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-12 | - | X-dag halvårsutdelning NOVO B 4.25 |
| 2022-08-04 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag halvårsutdelning NOVO B 6.9 |
| 2022-03-24 | - | Årsstämma |
| 2022-02-02 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2021-08-05 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-26 | - | X-dag halvårsutdelning NOVO B 5.85 |
| 2021-03-25 | - | Årsstämma |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-14 | - | X-dag halvårsutdelning NOVO B 3.25 |
| 2020-08-06 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-27 | - | X-dag halvårsutdelning NOVO B 5.35 |
| 2020-03-26 | - | Årsstämma |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | X-dag halvårsutdelning NOVO B 3 |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-22 | - | X-dag halvårsutdelning NOVO B 5.15 |
| 2019-03-21 | - | Årsstämma |
| 2019-02-01 | - | Bokslutskommuniké 2018 |
| 2018-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2018-08-08 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-02 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-23 | - | X-dag halvårsutdelning NOVO B 4.85 |
| 2018-03-22 | - | Årsstämma |
| 2018-02-01 | - | Bokslutskommuniké 2017 |
| 2017-11-01 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2017-08-09 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-03 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-24 | - | X-dag ordinarie utdelning NOVO B 4.60 DKK |
| 2017-03-23 | - | Årsstämma |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-12 | - | X-dag halvårsutdelning NOVO B 3 |
| 2016-08-05 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-21 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2016-03-18 | - | Årsstämma |
| 2016-02-03 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-06 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-30 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-20 | - | X-dag ordinarie utdelning NOVO B 5.00 DKK |
| 2015-03-19 | - | Årsstämma |
| 2015-01-30 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-07 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-01 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning NOVO B 4.50 DKK |
| 2014-03-20 | - | Årsstämma |
| 2014-02-03 | - | Bokslutskommuniké 2013 |
| 2014-01-02 | - | Split NOVO B 1:5 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-08 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-01 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-21 | - | X-dag ordinarie utdelning NOVO B 18.00 DKK |
| 2013-03-20 | - | Årsstämma |
| 2013-02-04 | - | Bokslutskommuniké 2012 |
| 2012-10-31 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-09 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-22 | - | X-dag ordinarie utdelning NOVO B 14.00 DKK |
| 2012-03-21 | - | Årsstämma |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-04 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-03-24 | - | X-dag ordinarie utdelning NOVO B 10.00 DKK |
| 2011-03-23 | - | Årsstämma |
| 2011-02-02 | - | Bokslutskommuniké 2010 |
| 2010-03-25 | - | X-dag ordinarie utdelning NOVO B 7.50 DKK |
| 2007-12-03 | - | Split NOVO B 1:2 |
| 2001-04-04 | - | Split NOVO B 1:5 |
| 1997-01-02 | - | Split NOVO B 1:2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
2026-02-11 21:14:05
Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 315.60 | 26,246 | |||||
| d) | Aggregated information
| 26,246 shares DKK 8,283,237.60 | ||||
| e) | Date of the transaction | 2026-02-10 | ||||
| f) | Place of the transaction | JANE STREET NETHERLANDS B.V. (JNSI) | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 315.70 | 311 | |||||
| d) | Aggregated information
| 311 shares DKK 98,182.70 | ||||
| e) | Date of the transaction | 2026-02-10 | ||||
| f) | Place of the transaction | CBOE EUROPE - DXE PERIODIC (NL) (BEUP) | ||||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 10 / 2026